We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Lower Killer T Cells Found in COVID-19 Patients Support ‘Prime and Boost’ Coronavirus Vaccine Model

By HospiMedica International staff writers
Posted on 14 Sep 2020
Researchers have discovered that killer T cells, key immune cells in fighting viral infections, are present at much lower levels in people with COVID-19, compared to influenza or glandular fever, thus lending support to the ‘prime and boost’ vaccine model.

The team from the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia) looked at 22 COVID-19 samples from patients who experienced asymptomatic, mild or moderate illness. More...
Their research concentrated on CD8 T cells (killer T cells), which are integral to mounting an effective and rapid recovery from viruses such as influenza. The team looked at T cells in people who express a protein called human antigen leucocyte (HLA) serotype HLA-A2. HLA proteins are important for T cell recognition and vary across individuals.

“What we found is those key immune cells weren’t stimulated optimally for rapid proliferation and expansion to fight SAR-CoV-2,” said first author, University of Melbourne’s Jennifer Habel, a PhD student at the Doherty Institute. “The magnitude of the killer T cells was only five times higher than those of the naïve immune cells. To give that perspective, it’s 10 times lower than what we see during an influenza or glandular fever response.”

In addition to magnitude, the team also looked at the activation profile of these immune cells and found that not only was activation poor, but in some cases these cells remained largely naïve, as if they had not been exposed to the virus at all. These striking findings support the ‘prime and boost’ vaccine model, according to the researchers.

“Knowing the specific T cells and proteins to target will inform the design of an effective vaccine,” said University of Melbourne Professor Katherine Kedzierska, a laboratory head at the Doherty Institute and a world-leading influenza immunology researcher who led this study. “This research shows that potentially, if a vaccine was able to prime the immune system of killer T cells and then boost them a short time later, the immune response is likely to be much more robust to fight SARS-CoV2.”

“If the SARS-CoV-2 virus is indeed compromising the killer T cell response that can be important for recovery, the best bet may be to get the right vaccine before the virus gets to us” said co-author, Doherty Institute Patron Laureate Professor Peter Doherty.

Related Links:
Peter Doherty Institute for Infection and Immunity


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Electrode Solution and Skin Prep
Signaspray
Digital X-Ray Detector Panel
Acuity G4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.